We tested two orally available LPA1 antagonists: SAR100842 [33] (US Patent 8,362,073 B2) was tested clinically in systemic sclerosis (Clinical Trial Identifier NCT01651143); EPGN9878 is in preclinical development (unpublished). The gene discussed is LPAR1; the disease is systemic sclerosis.